Skyline Diagnostics closes licensing agreement with Trovagene
AMLprofiler will be initially offered as a laboratory testing service in Europe and will be expanded to markets outside of Europe in the near future.
“The addition of NPM1 mutation testing to the AMLprofiler microarray renders it the most comprehensive in vitro diagnostic test on the market for Acute Myeloid Leukemia,” said Henk Viëtor, MD, Skyline Diagnostics’ Chief Executive Officer.
Acute Myeloid Leukemia is a cancer of the bone marrow in which the rapid proliferation of abnormal cells interferes with normal blood cell production. The AMLprofiler in vitro diagnostic test simplifies the recognition of AML subtypes by replacing 9 separate assays, combining cytogenetics, mutation analysis and expression analysis, in a single microarray-based test.
With the AMLprofiler, more than 50% of the intermediate risk group of AML patients can be reclassified into either the favorable or the unfavorable risk group, thus facilitating the clinical decision making process. The NPM1 mutation status is associated with good disease prognosis and may influence treatment options.
Source: Skyline Diagnostics
